On 4 June, 2021, Pharmaxis (ASX: PXS) hosted an investor briefing with CEO Gary Phillips to update investors on recent achievements and future plans, plus a Q&A with attendees.
Topics discussed in the briefing and question time included:
Company Summary
Pharmaxis is in a rare microcap air for a pharmaceutical research company that has a commercialised product at market with sales nearing profitability that can fund transformational cancer research. Addressing a substantial market opportunity through targeting of myelofibrosis where current treatment standards are limited, yet still sell upwards of USD $1 billion per year.
In May 2021, Emerald Financial published a research report on Pharmaxis which can be downloaded here.
After several challenging years for Australian retailers grappling with cost-of-living pressures and post-COVID inflation, eCommerce…
Australia’s industrial and IoT sectors are racing toward smarter, more autonomous sensing and one of…
As interest in neuromuscular activation tools accelerates across elite sport, Control Bionics Limited (ASX:CBL) is…
Australia’s data-centre construction sector continues to surge on the back of cloud adoption, AI-driven computing…
A major Australian research initiative is set to push forward global understanding of brain injury,…
Following a successful FY25 which saw a boost in gross profit after launching its refurbished…